Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Updates on hormone receptor-positive HER2-negative breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.07.19
Views: 579
Rating:

Dr Aurelio Castrellon - Memorial Healthcare System, Hollywood, FL, USA

Dr Aurelio Castrellon speaks to ecancer at the 2019 ASCO Direct Highlights Symposium in Miami about the important developments in the treatment of hormone receptor-positive HER2-negative breast cancer.

He describes two main studies in patients with stage IV breast cancer, specifically in premenopausal patients and includes the MONALEESA-7 trial and the KCSG-BR 15-10 study.

Dr Castrellon also details two further studies which assessed the use of pembrolizumab combined with eribulin in this disease setting and the combination of fulvestrant with capivasertib (an AKT-inhibitor).

He concludes by mentioning the mutation FAT1, which may confer intrinsic resistance to CDK4/6 inhibition in these patients.

 

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation